PT  - JOURNAL ARTICLE
AU  - Christos M Polymeropoulos
AU  - Michael A Mohrman
AU  - Madison S Keefe
AU  - Jennifer L Brzezynski
AU  - Jingyuan Wang
AU  - Lydia S Prokosch
AU  - Vasilios M Polymeropoulos
AU  - Changfu Xiao
AU  - Gunther Birznieks
AU  - Mihael H Polymeropoulos
TI  - Tasimelteon (HETLIOZ®) effective in the treatment of Jet Lag Disorder in an 8-hour phase advance; a multicenter, randomized, double-blind, placebo-controlled trial
AID  - 10.1101/2020.04.07.20053306
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.07.20053306
4099  - http://medrxiv.org/content/early/2020/04/10/2020.04.07.20053306.short
4100  - http://medrxiv.org/content/early/2020/04/10/2020.04.07.20053306.full
AB  - Background Travelers frequently experience Jet Lag Disorder (JLD) symptoms due to misalignment of the circadian rhythm with respect to the new time zone. In the JET8 Study, we assessed the efficacy and safety of tasimelteon (HETLIOZ®) in healthy participants using a laboratory model of JLD induced by an 8-h phase advance of the sleep-wake cycle. We hypothesized that tasimelteon treatment in participants experiencing JLD would cause increased sleep time, increased next-day alertness, and reduced next-day sleepiness.Methods We undertook a randomized, double-blind, placebo-controlled trial in 12 US clinical research sleep centers. We screened healthy adults ages 18-73 years, who were eligible for the randomization phase of JET8 if they typically went to bed between 21:00 and 01:00, slept between 7-9 hours each night, and slept at a consistent bedtime. We used block randomization stratified by site to assign participants (1:1) to receive a single oral dose of tasimelteon (20mg) or placebo 30 min before their 8-h phase-advanced bedtime. The primary endpoint was Total Sleep Time in the first 2/3 of the night (TST2/3), which was measured by polysomnography during the 8-h sleep episode, and assessed in the intent-to-treat population. The trial is completed and registered with ClinicalTrials.gov, NCT03373201.Results Between October 16, 2017 and January 17, 2018, we screened 607 healthy participants for JET8, of whom 320 (53%) were assigned to receive tasimelteon (n=160) or placebo (n=160). Tasimelteon treatment resulted in increased TST2/3 by 60.3 min (95%CI 44.0 to 76.7, P<0.0001) compared to placebo and had a highly significant benefit in secondary endpoints including TST of the whole night, next day alertness, next day sleepiness, and latency to persistent sleep.Conclusion A single dose of tasimelteon improves symptoms, including sleep and next day functioning in participants, following an 8-h phase advance of the sleep-wake cycle in a laboratory model of JLD simulating eastward trans-meridian travel.Competing Interest StatementThe clinical trial was sponsored by Vanda Pharmaceuticals. CMP, MSK, JLB, MAM, VMP, LSP, GB, JW, CX, and MHP are employees of Vanda Pharmaceuticals.Clinical TrialNCT03373201Funding StatementThe study was funded by Vanda Pharmaceuticals Inc.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe original contributions presented in the study are included in the article/supplementary files, further inquiries can be directed to the corresponding author/s.